Please use this identifier to cite or link to this item:
|Title:||Proinsulin C-Peptide Antagonizes the Profibrotic Effects of TGF-β1 via Up-Regulation of Retinoic Acid and HGF-Related Signaling Pathways|
|Other Titles:||Microarray analysis reveals up-regulation of retinoic acid and hepatocyte growth factor related signaling pathways by pro-insulin C-peptide in kidney proximal tubular cells: Antagonism of the pro-fibrotic effects of TGF-β1|
|Authors:||Hills, Claire E.|
Willars, Gary B.
Brunskill, Nigel J.
|Citation:||Molecular Endocrinology, 2010, 24 (4), pp. 822-831.|
|Abstract:||Novel signaling roles for C-peptide have recently been discovered with evidence that it can ameliorate complications of type 1 diabetes. Here we sought to identify new pathways regulated by C-peptide of relevance to the pathophysiology of diabetic nephropathy. Microarray analysis was performed to identify genes regulated by either C-peptide and/or TGF-β1 in a human proximal tubular cell line, HK-2. Expression of retinoic acid receptor β (RARβ), hepatocyte growth factor (HGF), cellular retinoic acid-binding protein II (CRABPII), vimentin, E-cadherin, Snail, and β-catenin was assessed by immunoblotting. The cellular localization of vimentin and β-catenin was determined by immunocytochemistry. Changes in cell morphology were assessed by phase contrast microscopy. Gene expression profiling demonstrated differential expression of 953 and 1458 genes after C-peptide exposure for 18 h or 48 h, respectively. From these, members of the antifibrotic retinoic acid (RA)- and HGF-signaling pathways were selected. Immunoblotting demonstrated that C-peptide increased RARβ, CRABPII, and HGF. We confirmed a role for RA in reversal of TGF-β1-induced changes associated with epithelial-mesenchymal transition, including expression changes in Snail, E-cadherin, vimetin, and redistribution of β-catenin. Importantly, these TGF-β1-induced changes were inhibited by C-peptide. Further, effects of TGF-β1 on Snail and E-cadherin expression were blocked by HGF, and inhibitory effects of C-peptide were removed by blockade of HGF activity. This study identifies a novel role for HGF as an effector of C-peptide, possibly via an RA-signaling pathway, highlighting C-peptide as a potential therapy for diabetic nephropathy.|
|Rights:||This paper was published as Molecular Endocrinology, 2010, 24 (4), pp. 822-831. Copyright © 2010 by The Endocrine Society. It is also available from the journal website at http://press.endocrine.org/doi/abs/10.1210/me.2009-0391 . Doi: 10.1210/me.2009-0391|
|Appears in Collections:||Published Articles, Dept. of Infection, Immunity and Inflammation|
Items in LRA are protected by copyright, with all rights reserved, unless otherwise indicated.